A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

To join this study, you would need to be an adult with a confirmed diagnosis of diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia. Importantly, your cancer must have either come back after previous treatment or not responded well to other medicines.

Also, your doctors need to be able to see and measure your cancer, meaning it's visible enough to track its progress. You will also need to have healthy enough blood test results to take part in the study, and if you've had a specific type of therapy before, you might need an extra biopsy (a small tissue sample).

There are also some reasons why you might not be able to join. For example, if your cancer has spread to your brain or spinal cord, or if you have an active infection. Your overall health and how well you can go about your daily activities will also be considered.

If you choose to join this study, you will receive the study drug ABBV-319, which is given directly into a vein. This will happen in repeating 21-day cycles. Initially, doctors will test different doses to find the best amount, and then other participants will receive that specific dose. You will need to attend regular appointments at a hospital or clinic approved for the study. These visits will involve various checks to see how you are doing, including medical examinations, blood tests, and answering questions about your health and how you feel. Doctors will also closely watch for any side effects. There might be more visits and tests than you would usually have for your standard cancer care.